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ABSTRACT 
        A simple, highly selective and stability-indicating high-performance thin-layer chromatographic method was developed 
and validated for the analysis of baclofen  in bulk powder, pharmaceutical formulations and human urine and in and real 
human plasma. The method employed TLC aluminum plates precoated with silica gel 60 F254 as the stationary phase. The 
solvent system consisted of butanol–acetic acid–water (3.0: 0.5: 0.5, v/v/v). This system was found to give compact spots 
for baclofen (Rf value of 0.54). Densitometric analysis was carried out in the absorbance mode at 238 nm. The linear 
regression analysis data for the calibration plot showed good linear relationship (r
2
 = 0.9983) in the concentration range 
1.5-7.5 µg per spot. The analytical performance of the method was fully validated, and the results were satisfactory. The 
limits of detection and quantitation were 0.31 and 1.03 µg per spot, respectively. Baclofen was subjected to acid and alkali 
hydrolysis, oxidation and photodegradation. The degraded product was well separated from the pure drug. Results 
indicate that the drug is stable against light and basic conditions. However, additional peaks were observed at Rf value of 
0.65 and at Rf value of 0.14 with hydrogen peroxide and hydrochloric acid respectively, indicating that the drug is 
susceptible to oxidation and acid degradation. The method was applied for the analysis of baclofen in commercial tablets 
and the results were similar to those obtained using the reference method. As the method could effectively separate the 
drug from its degradation product, it can be employed as a stability-indicating one. The high sensitivity of the proposed 
method allowed determination of baclofen in real human urine and plasma. 
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1. INTRODUCTION 
      Baclofen (4-amino-3-p-chlorophenyl butyric acid, BAL, “Figure 1”, the first clinical application of selective γ-
aminobutyric acid has been widely used for the symptomatic relief of muscular spasm and multiple sclerosis caused by 
spinal or cerebral injury since its introduction in 1967 [1]. Unlike natural amino acids, BAL is capable of passing a blood–
brain barrier. It is rapidly adsorbed in the human body after oral administration and almost completely recovered 
unchanged in urine [2]. Its metabolism and mechanism of pharmacological action in humans is still poorly recognized. 
Consequently, development of a highly sensitive and specific method for the trace analysis of BAL is urgently required. 
Several analytical methods have been reported for the determination of BAL. These methods include; spectrophotometry 
[3, 4], potentiometry [5], thin-layer chromatography [6], gas chromatography [7], capillary electrophoresis [8, 9] and high-
performance liquid chromatography (HPLC) coupled with different kinds of detectors [10 - 17]. For HPLC with conventional 
detection systems, such as UV–vis or fluorescence detectors, BAL needs to be derivatized because solution of BAL does 
not show obvious absorption or fluorescence. For this reason, chemical several derivatizing reagents [11-17] were applied 
to transform the analytes into derivatives that can be sensitively detected. 
N
H
H
OO
H
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Fig 1: Chemical structure of baclofen (BAL) 
The International Conference on Harmonization (ICH) guideline entitled ‘stability testing of the drug substances and 
products’ requires the stress testing to be carried out to elucidate the inherent stability characteristics of the active 
substance [18]. An ideal stability-indicating method is one that quantifies the drug per se and also resolves its degradation 
products. Nowadays, HPTLC is becoming a routine analytical technique in analytical laboratories due to its advantages 
[19]. The major advantage of HPTLC is that several samples can be run simultaneously using a small quantity of mobile 
phase [19]. This reduces analysis time, cost per analysis and possibilities of pollution of the environment. The aim of the 
present work is to develop a simple, and promising stability-indicating densitometric method that can be applied at quality-
control laboratories for the estimation of baclofen in pure form, in pharmaceutical tablets and in artificially degraded 
sample.  
2. EXPERIMENTAL 
2.1. Materials 
Baclofen was obtained as a gift from Novartis Pharma, (Cairo, Egypt). All chemicals and reagents used were of analytical 
grade. Acetic acid, hydrochloric acid, hydrogen peroxide (30 volume), sodium hydroxide and Butanol were purchased from 
El-Nasr Chemical Co. (Cairo, Egypt). baclofen tablets (Novartis Pharma, Cairo, EGYPT), (Pharopharma A.R.E., Cairo, 
EGYPT) and (Misr, Cairo, EGYPT) labeled to contain 10 mg baclofen were purchased from local mark. 
2.2. HPTLC instrumentation  
Chromatographic separation was performed on aluminum plate precoated with silica gel 60F254, (20 cm × 10 cm with 250 
µm thickness) (Merck, Darmstadt, Germany). The samples were spotted with a Camag micro-syringe 100 µl, using a 
Camag Linomat 5 autosampler, (Camag, Muttenz, Switzerland). Densitometric scanning was performed on Camag TLC 
scanner 3 S / N 130319 in the absorbance mode utilizing deuterium lamp as a source of radiation with WINCATS software 
(Camag, Muttenz, Switzerland). 
2.3. Chromatographic conditions 
   Aliquot amount of the working standard or sample solutions were spotted on the plate in the form of bands of width 3 
mm with 100 µl micro-syringe, using autosampler. A constant application rate of 0.1 μl/s was employed and space 
between two bands was 3 cm. The bands were applied at 1 cm from the bottom edge of the plate. The plate was then 
allowed to dry on air for 5 min before its transfer to the TLC tank for the development. The mobile phase consisted of 
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butanol–acetic acid–water (3.0: 0.5: 0.5, v/v/v).. Linear ascending development was carried out in chromatographic 
chamber previously saturated with the mobile phase for 15 min at room temperature. The length of chromatogram run was 
8 cm subsequent to the development. TLC plates were dried in a current of air with the help of an air-dryer. Densitometric 
scanning was performed at 20 mm/s scanning speed and the slit dimension was kept at 6.0 × 0.30 µm. The TLC 
chromatogram was manipulated by WINCATS software. 
2.4. Standard solution preparation 
  Stock solutions containing baclofen were prepared by dissolving 30 mg of baclofen in 1 ml 0.05 M H2SO4 and completed 
to 10 ml with methanol. 
2.5. Calibration curves of baclofen 
      Different volumes of stock solution, 0.5, 0.9, 1.3, 1.7, 2.1 and 2.5 μl, were spotted in triplicate on TLC plate to obtain 
concentrations of 1.5, 2.7, 3.9, 5.1, 6.3 and 7.5 μg per spot of baclofen, respectively, then the densitometric analysis was 
performed as described under the Section 2.3. The calibration curve was established by plotting the average peak area 
versus the corresponding concentration of the spot and the data was analyzed by least-square linear regression analysis 
and the linear regression equation was estimated. 
2.6. Method validation 
2.6.1. Precision 
     Precision was checked at three concentration levels (1.5, 3.9 and 6.3 μg per spot), four replicate measurements were 
recorded at each concentration level. 
2.6.2. Robustness of the method 
    The robustness of the proposed method was examined by introducing small changes in the mobile phase composition 
and examining wavelength. Mobile phases having different composition of butanol–acetic acid–water (2.9: 0.6: 0.5 and 
3.1: 0.4: 0.5, v/v/v.  and different wave length (233 nm and 243nm) were tried at three different concentration levels of  
(1.5, 3.9 and 6.3 μg per spot). 
2.6.3. Recovery studies 
   Aliquot amounts of the dosage forms extract were spiked with extra 50, 100 and 150 % of the standard baclofen and the 
mixtures were reanalyzed in triplicate by the proposed method. This was done to check for the recovery of the drug at 
different levels in the formulations. 
2.7. Analysis of the commercial formulation 
   The content of baclofen in three commercial formulation (Baclofen: 10 mg per tablet, Lioresal: 10 mg per tablet and 
Mylobac: 10 mg per tablet), Ten tablets of baclofen were accurately weighed and finely powdered. An amount of the 
powdered tablets was accurately weighed equivalent to 150 mg of baclofen and extracted with 5 ml 0.05 M H2SO4 and 20 
ml with methanol by sonication for 30 min. Then completed to 50 ml with methanol. The resulting solution was centrifuged 
at 3000 rpm for 5 min and supernatant was analyzed for drug content. Four replicates at three concentration levels (1.5, 
3.9 and 6.3 μg per spot of baclofen) were applied on TLC plate followed by development and scanning as described in  
Section 2.3. 
2.8. Forced degradation of baclofen 
     Acid and base induced degradation were carried out by adding 5 ml of 5 N aqueous HCl or 5 N aqueous NaOH to 20 
ml of baclofen working solution (3mg/ml). The mixtures were heated at reflux for 6 hrs. Oxidative degradation with 
hydrogen peroxide (30.0 % v/v) was carried out at the same manner but without reflux. These degradation procedures 
were performed in the dark in order to exclude the possible degradative effect of light. Photochemical stability was studied 
by exposing the working solution to direct daylight for 24 h. The resultant solution was applied on TLC plate (1.5 μg/spot) 
and the chromatograms were run as described in Section 2.3. 
2.9 Real human plasma of baclofen 
      Procedure for Real Human Plasma baclofen (Lioresal 25 mg tablet) was taken orally by 12 hours fasting healthy 
human volunteers, then a 5.0-ml sample of human blood was taken by using calibrated heparinized syringe after 3 h from 
baclofen taken [24], centrifuged at 4,000 rpm for 30 min. Then, into a 10-ml stoppered calibrated tube, 1.0 ml of obtained 
plasma was treated with 2.0 ml of acetonitrile, and the resultant solution was diluted to 10.0 ml with distilled water. The 
sample was centrifuged at 4,000 rpm for 20min. A certain volume of this supernatant was diluted with methanol to obtain 
concentration within the concentration range for studied drug. Then, the chromatograms were run as described in Section 
2.3. This process was repeated three times to accomplish intraday and interday assay. 
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2.10 Real human urine of baclofen 
      Procedure for Real Human Urine baclofen (Lioresal 25 mg tablet) was taken orally by 12 hours fasting healthy human 
volunteers, and the urine samples were collected 12 h after the administration and stored in flasks at - 20°C prior to 
analysis [24]. Acertain volume of this sample was diluted with methanol to obtain concentration within the concentration 
range for studied drug. Then, the chromatograms were run as described in Section 2.3. This process was repeated three 
times to accomplish intraday and interday assay. 
3. RESULTS AND DISCUSSION 
3.1. Method development 
    TLC procedure was optimized with a view to develop a stability-indicating assay method. Both the pure drug and the 
degraded one were spotted on TLC plates and run in different solvent systems. Initially, butanol–acetic acid in varying 
ratios was tried. The mobile phase butanol–acetic acid (3.0: 0.5, v/v) gave good resolution with RF value of 0.56 for 
baclofen and 0.65, 0.14 for degradation with hydrogen peroxide and hydrochloric acid respectively but the peaks have 
tailing. Addition of 0.5 ml water to the above mobile phase gave compact spots for both drug and the degradant. Finally, 
the mobile phase consisting of butanol–acetic acid–water (3.0: 0.5: 0.5, v/v/v) gave a sharp and symmetrical peak. Well-
defined spots were obtained when the chamber was saturated with the mobile phase for 15 min at room temperature. 
3.2. Method validation 
Validation was done following the ICH guidelines [21].The method was validated in terms of linearity, accuracy, inter-day 
and intra-day precision, robustness, and  repeatability of sample application.  
Linearity: “Figure 2” illustrate the linear calibration curve which constructed for baclofen by measuring the peak areas 
of triplicate bands at ten increasing concentrations 1.5, 2.7, 3.9, 5.1, 6.3, 7.5 μg per spot of baclofen .The curves were 
constructed by plotting the average peak areas against the corresponding concentration of the spot. Linear regression 
analysis was applied to calculate the analytical parameters of the constructed curve. The linear regression analysis data 
for the calibration plots showed good linear relationship with regression coefficients (r
2
) of 0.9983 over the concentration 
range 1.5-7.5 µg per spot. 
 
Fig 2: Chromatograms of pure baclofen (Rf: 0.54) using silica gel 60F254 as the stationary phase, mixture of 
butanol–acetic acid–water (3.0: 0.5: 0.5, v/v/v) as mobile phase and absorbance mode at 238nm. 
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Limit of detection (LOD) and limit of quantitation (LOQ): were calculated based on standard deviation of 
response and the slope of calibration curve. The limit of detection was expressed  
as: LOD = 3 σ / S whlie LOQ= 10 σ / S 
 Where σ is the standard deviation of intercept.  S is the slope of calibration curve. 
“Table 1”, Summarize the result of the calculated detection limits and quantitation were 0.31 and 1.03 μg per spot, 
respectively, indicating the high sensitivity of the proposed method.  
 
Table 1. Analytical  parameters for the proposed TLC method for determination of  baclofen. 
Parameters Results 
Linearity Range (µg/spot) 1.5-7.5 
Correlation coefficient (r) 0.9991 
Determination coefficient (r
2
) 0.9983 
Intercept (a) ± SD 261.8 ± 71.8 
Confidence limit of intercept 
b
 157.56 
Slope (b) ± SD 333.07 ± 13.6 
Confidence limit of slope 
b
 312.04 
LOD (µg /spot) 0.31 
LOQ (µg /spot) 1.03 
(a)
  Number of determination is 6.   
(b)
  95% confidence limit. 
 
Precision: The repeatability of sample application was expressed in terms of % RSD. The intra- and inter-day 
precisions were carried out at three different concentration levels, i.e. 1.5, 3.0, 6.3 μg /spot. “Table 2”, Summarize the 
result of Inter- and intra-day precision study and the repeatability of sample application. The calculated relative standard 
deviation values were below 2 % indicating good repeatability and reliability of the proposed method [21] and [22]. 
Table 2. The repeatability of sample application and Intra- and inter-day precision for the determination of 
baclofen by the proposed HPTLC method. 
Amount 
(µg per spot) 
Intra-day precision Inter-day precision 
% Recovery
 a 
± % RSD SE % Recovery
 a
 ± % RSD SE 
1.5 
 
99.6 ± 1.33 
 
0.66 
 
98.2 ± 0.27 
 
0.16 
 
3.0 
 
99.7 ±  1.24 
 
0.62 
 
98.5 ± 0.30 
 
0.17 
6.3 
 
99.9 ± 1.19 
 
0.60 
 
99.5 ± 1.11 
 
0.64 
a
 the value is the average of four determinations. 
 
Robustness: “Table 3”, Summarize the result of the robustness of the method which carried out by introducing small 
changes in the mobile phase composition, wave length, and examining the effects on the results.  By spotting three 
different concentration levels of 1.5, 3.0, 6.3 μg /spot .It was found that there is no change in the results. 
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Table 3. Robustness for determination of baclofen by the proposed HPTLC method. 
 
Variation 
% Recovery
 a
 ± % RSD 
        1.5 (µg per spot) 3.0 (µg per spot)                 6.3 (µg per spot)     
 
Optimum 
condition 
 
99.1 ± 0.8 
           
         99.9 ± 1.2 
 
99.9 ± 0.4 
 
       
1-Mobile phase composition        butanol–acetic acid–water (3.0 : 0.5 : 0.5, v/v/v) 
 
(2.9 : 0.6 : 0.5) 
 
99.1 ±  0.7 
 
99.1 ± 1.1 
 
98.8 ± 1.2 
 
(3.1 : 0.4 : 0.5) 99.5 ± 0.9 100.2 ± 0.8 99.2 ± 0.6  
2- Wave length changes                                 238 nm 
      233 nm                                98.4 ± 0.8                           99.7 ± 1.2                          100.1 ± 0.9 
      243 nm                                99.0 ± 1.5                          100.0 ± 0.5                          99.0 ± 1.3 
a
 the value is the average of four determinations. 
 
Accuracy: Recovery studies of the drugs were carried out for estimation of the accuracy parameters of the proposed 
method. These studies were carried out at three levels i.e. using standard addition method. The obtained value for the 
commercial formulation was found to be within the limits which summarized in “Table 4”, The low RSD value (< 2) 
indicated the suitability of the method for routine analysis of baclofen in pharmaceutical tablets. 
 
Table 4. Standard addition method for the recovery studies 
% Drug added Total content (µg/ spot) % Recovery 
a
 ± SD SE 
0 1.5 99.2 ± 0.61 0.35 
50 2.25 99.6 ± 1.72 0.99 
100 3 98.0 ± 0.89 0.50 
150 3.75 99.4 ± 1.43 0.82 
a: the value is the average of three determinations. 
 
3.3. Stability-indicating study 
  The stability of baclofen solution was examined at different stress conditions. 5 N aqueous HCL “Figure 3b” results in 
the appearance of an additional peak at Rf value of 0.14, The new peak appears before the parent drug peak. This gives 
an indication that the degradation product is more hydrophilic than the parent drug, while oxidation with hydrogen peroxide 
“Figure 3d” result in the appearance of an additional peak at Rf value of 0.65, the new peak appears after the parent drug 
peak. This gives an indication that the degradation product is more lipophilic than the parent drug. The exposure to 
alkaline hydrolysis and daylight (“Figure 3a, 3e”, respectively) did not produce any significant effect on the drug 
chromatograms and only one peak was observed at Rf = 0.54 which corresponds to baclofen itself. This is an evidence of 
the stability of baclofen against alkaline hydrolysis and photodegradation and liability of baclofen for acidic hydrolysis and 
oxidative degradation. 
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Fig  3: Chromatograms of baclofen and its degraded products: (a) pure drug: peak 1 (Rf: 0.54) is of baclofen; (b) 
degraded with acid: peak 1 (Rf: 0.14) is of degraded product, peak 2 (Rf: 0.54) is of baclofen; (c) base-treated: peak 
1 (Rf: 0.54) is of baclofen; (d) degraded with hydrogen peroxide: peak 1 (Rf: 0.54) is of baclofen, peak 2 (Rf: 0.65) is 
of degraded product; (e) photo-treated: peak 1 (Rf: 0.54) is of baclofen. 
3.4. Application to commercial tablets 
  The chromatogram of the drug samples extracted from commercial formulation showed only one spot at R f 0.54. It may 
therefore be inferred that the degradation of baclofen had not occurred in the analyzed commercial formulation. The 
presence of excipients in the tablets did not produce any significant interference with the analysis. The result of the 
present method was statistically compared with that of the reference method [23]. “Table 5”,  shows that the calculated t- 
and F- values at 95% confidence level are less than the tabulated t- value (2.13) and F value (4.10).  This confirms that 
there is no significant difference between the performance of the developed method and the reference method in regarded 
to accuracy and precision. 
 
Table 5. Analysis of commercial tablets containing baclofen using the proposed and reported methods. 
 
Dosage 
forms 
 
Labeled 
content 
% Recovery ± SD
 a
  
t- value 
b
 
 
F- value 
b 
 
Reported method 
 
Proposed method 
 
Baclofen 
 
10 mg 
 
100.2 ± 0.87 
 
98.9 ± 0.80 
 
1.62 
 
1.21 
 
Lioresal 
 
10 mg 
 
99.7 ± 0.29 
 
99.0 ± 0.40 
 
1.05 
 
1.96 
 
Mylobac 
 
10 mg 
 
99.9 ± 0.49 
 
99.1 ± 0.32 
 
1.28 
 
2.36 
a
 Average of three determinations.   
b 
Tabulated values for t and F. are 2.13 and 4.10 respectively. 
 
 
e 
d 
c 
b 
a 
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3.5 Analysis of cited drug in Real Human Plasma  
Baclofen is rapidly and completely absorbed from the gastro-intestinal tract. baclofen is absorbed rapidly after oral 
administration of 25 mg producing a mean peak plasma concentration of 20 mg/L in 3 h [24]. So, percent recovery of 
baclofen in plasma was calculated by using the following equation [25]. 
% Recoveryin vivo =  (concentration found / concentration taken)  × 100 
 
Where, 
% Recovery in vivo is % recovery for drug in real human sample. 
Concentration found is concentration of the drug founded in real human sample. 
Concentration taken is concentration of the drug reported in real human sample. 
 Percent recoveries after application of the proposed method in real human plasma sample by intra- and interday assay 
were shown in “Table 6”, “Figure 4” illustrate the chromatogram of analysis of baclofen in real human plasma. 
 
Table 6. % Recoveries after application of the proposed method for determination of baclofen in real human 
plasma sample. 
Drug 
Concentration taken 
(µg/ spot) 
Concentration found 
(µg/ spot) 
    Percent recoveryin vivo 
(A) Intraday assay  1.19 79.3 
 1.5 1.28 85.3 
  1.22 81.3 
Mean ± S.D.   81.9 ± 3.0 
(B) Interday assay  1.09 72.6 
 1.5 1.18 78.7 
  1.16 77.3 
Mean ± S.D.   76.2 ± 3.2 
 
 
Fig 4: Chromatograms of baclofen in Real Human Plasma. 
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3.6 Analysis of cited drugs in Real Human Urine  
Approximately 70% of baclofen is eliminated in urine in unchanged form. Baclofen is absorbed rapidly after oral 
administration of 25 mg producing a mean peak elimination concentration of 17.5 mg/L in 3 h [24]. So, percent recovery of 
baclofen in urine was calculated by using the following equation. 
% Recovery in vivo = (concentration found / concentration taken) × 100 
 
Where, 
% Recovery in vivo is % recovery for drug in real human sample. 
Concentration found is concentration of the drug founded in real human sample. 
Concentration taken is concentration of the drug reported in real human sample. 
 Percent recoveries after application of the proposed method in real human urine sample by intra- and interday assay were 
shown in “Table 7”, “Figure 5” illustrate the chromatogram of analysis of baclofen in real human plasma. 
  
Table 7. % Recoveries after application of the proposed method for determination of baclofen in real human urine 
sample. 
Drug 
Concentration taken 
(µg/ spot) 
Concentration found 
(µg/ spot) 
% recovery in vivo 
(A) Intraday assay  1.30 86.7 
 1.5 1.35 90.0 
  1.29 86.0 
Mean ± S.D.   87.6 ± 2.1 
(B) Interday assay  1.25 83.3 
 1.5 1.31 87.4 
  1.26 84.0 
Mean ± S.D.   84.9 ± 2.2 
 
 
Fig 5: Chromatograms of baclofen in Real Human Urine. 
4. CONCLUSION 
  In this work, HPTLC technique was developed and validated for determination of baclofen in bulk, pharmaceutical tablets 
and in real human urine and plasma. The proposed method is simple, accurate and highly selective for baclofen. It could 
be extended to study the stability of baclofen under different stress conditions. As the method separates the drug from its 
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degradation product, it can be considered as a stability-indicating one. The satisfactory sensitivity and simplicity make the 
methods suitable for routine analysis of baclofen in quality control laboratories.  
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